Thank you very much, Madam Chair. Thank you for being here and presenting to us today.
I think we have been in a long learning curve in this committee, and what you have added here today has certainly helped us.
We've had a fair amount of discussion today about adjuvanted and non-adjuvanted. I would ask Dr. Griffiths to make some further comments about safety for pregnant women.
In your presentation you talked about how adjuvanted vaccines may also provide broader cross-protection across mutating flu virus strains. I think Mr. Lucas referred to that, as well as Dr. Butler-Jones. I would like you to speak to that mutation and try to explain it to a layperson here--and also, what the ramifications of immunization or non-immunization will have with this mutation, if there is any relationship.